Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade ...

REPL

<p>口頭報告的生物標誌物數據顯示，RP1 聯合 nivolumab 在經過明確的抗 PD-1 治療失敗後，能夠逆轉晚期黑色素瘤中多種對 PD-1 阻斷的耐藥機制</p>

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer  ( SITC 2025 ) 

Replimune 在第 40 屆癌症免疫治療學會年會上展示 RP1 的最新突破性摘要和其他海報